Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion submitted a Phase 3 Clinical Trial Application (CTA) to the Ministry of Food and Drug Safety (MFDS) of South Korea for CT-P51, a biosimilar candidate referencing Keytruda, targeting patients with metastatic non-squamous non-small cell lung cancer.
📊 Key Disclosure Content & Financial Highlights
- Overview
- Company: Celltrion, Inc. (Stock Code: 068270)
- Disclosure Type: Major Matters Report Related to Investment Decisions
- Subject: Application for Phase 3 Clinical Trial Plan for CT-P51 (Keytruda Biosimilar) in South Korea
- Reviewing Authority: Ministry of Food and Drug Safety (MFDS), South Korea
- Application & Confirmation Date: 2025-01-15 (Date clinical trial plan was submitted to MFDS)
- Clinical Trial Details
- Study Title: A Double-Blind, Randomized, Active-Controlled, Parallel-Group Phase 3 Trial to Compare the Efficacy and Safety of CT-P51 and Keytruda in Combination with Platinum-Pemetrexed Chemotherapy in Previously Untreated Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase: Global Phase 3
- Target Indication: Metastatic non-squamous non-small cell lung cancer (NSCLC)
- Registration Number: EU CT number 2024-514048-98-00
- Patient Count: 606 subjects
- Duration: 2-year treatment period
- Purpose: To compare efficacy and safety between CT-P51 and the reference drug Keytruda to demonstrate biosimilarity
- Regulatory Process & Investment Risks
- Celltrion plans to demonstrate biosimilarity to Keytruda and seek approval across all reference indications including non-small cell lung cancer.
- Statistically, the probability of a clinical-stage drug candidate receiving final authorization is approximately 10%. Commercialization plans may be altered or abandoned based on trial outcomes.
- Content of this disclosure will be utilized in upcoming press releases and IR materials.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Approval Status of Phase 3 Clinical Trial Plan in Korea
This disclosure serves as official notification that Celltrion has submitted its Phase 3 Clinical Trial Plan to the MFDS. Tracking whether regulatory review concludes with official approval of the trial plan is important for assessing the actual implementation of the clinical trial. Relevant updates can be confirmed through subsequent approval disclosures or official IR announcements.
📢 Disclaimer & Source Notice
Source: This content was structured and generated based on official disclosure data from the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
